Safety, Pharmacokinetics and Pharmacodynamics of Recombinant Chimeric Anti-CD20 Monoclonal Antibody in Patients With B-cell Non-Hodgkin's Lymphoma.
The purpose of this study is to determine whether SCT400 is safe and effective in the treatment of B-cell Non Hodgkin's lymphoma
B-cell Non Hodgkin's Lymphoma
BIOLOGICAL: Chimeric anti-CD20 monoclonal antibody
Number of participants with infusion-related reaction and with drug-related adverse events., up to 27 weeks
Area Under the plasma concentration versus time curve (AUC) of SCT400, prior to the initial dose on day 1 and 0,2,4,8,24,48,72,96,120 hours post-dose
Time to disease progression, up to 27 weeks
The purpose of this study is to determine whether SCT400 is safe and effective in the treatment of B-cell Non Hodgkin's lymphoma